...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >A synthetic kainoid, (2S,3R,4R)-3-carboxymethyl-4-(phenylthio)pyrrolidine-2-carboxylic acid (PSPA-1) serves as a novel anti-allodynic agent for neuropathic pain.
【24h】

A synthetic kainoid, (2S,3R,4R)-3-carboxymethyl-4-(phenylthio)pyrrolidine-2-carboxylic acid (PSPA-1) serves as a novel anti-allodynic agent for neuropathic pain.

机译:合成的类胡萝卜素,(2S,3R,4R)-3-羧甲基-4-(苯硫基)吡咯烷-2-羧酸(PSPA-1)可作为新型抗痛觉过敏药治疗神经性疼痛。

获取原文
获取原文并翻译 | 示例
           

摘要

In spite of prominent progress in basic pain research, neuropathic pain remains a significant medical problem, because it is often poorly relieved by conventional analgesics. Thus this situation encourages us to make more sophisticated efforts toward the discovery of new analgesics. We previously showed that i.t. administration of acromelic acid-A (ACRO-A), a Japanese mushroom poison, provoked prominent tactile pain (allodynia) at an extremely low dose of 1 fg/mouse. In the present study we synthesized ACRO-A analogues (2S,3R,4R)-3-carboxymethyl-4-phenoxypyrrolidine-2-carboxylic acid (POPA-2) and (2S,3R,4R)-3-carboxymethyl-4-(phenylthio)pyrrolidine-2-carboxylic acid (PSPA-1) chemically and examined their ability to induce allodynia in conscious mice. Whereas POPA-2 induced allodynia at extremely low doses from 1 to 100 fg/mouse, similar to ACRO-A, PSPA-1 did not induce allodynia; rather, it inhibited the ACRO-A-induced allodynia with an ID(50) value (95% confidence limits) of 2.19 fg/mouse (0.04-31.8 fg/mouse). Furthermore, PSPA-1 relieved neuropathic pain produced by L5 spinal nerve transection on day 7 after the operation in a dose-dependent manner from 1 to 100 pg/mouse. In contrast, it did not affect thermal or mechanical nociception or inflammatory pain. PSPA-1 reduced the increase in neuronal nitric oxide synthase activity in the spinal cord of neuropathic pain mice assessed by NADPH-diaphorase histochemistry and blocked the allodynia induced by N-methyl-d-aspartate. These results demonstrate that PSPA-1 may represent a novel class of anti-allodynic agents for neuropathic pain acting by blocking the glutamate-nitric oxide pathway.
机译:尽管基本疼痛研究取得了显着进展,但神经性疼痛仍然是一个重大的医学问题,因为常规镇痛药通常无法很好地缓解神经痛。因此,这种情况鼓励我们为发现新的止痛药做出更复杂的努力。我们之前已经证明过施用日本蘑菇毒Acromelic Acid-A(ACRO-A),以极低的剂量1 fg /小鼠引起明显的触觉疼痛(异常性疼痛)。在本研究中,我们合成了ACRO-A类似物(2S,3R,4R)-3-羧甲基-4-苯氧基吡咯烷-2-羧酸(POPA-2)和(2S,3R,4R)-3-羧甲基-4- (苯硫基)吡咯烷-2-羧酸(PSPA-1)的化学性质,并检查了它们在有意识的小鼠中诱发异常性疼痛的能力。尽管POPA-2以1至100 fg /小鼠的极低剂量诱导异常性疼痛,类似于ACRO-A,但PSPA-1并未诱发异常性疼痛。相反,它以2.19 fg /小鼠(0.04-31.8 fg /小鼠)的ID(50)值(95%置信限)抑制了ACRO-A诱导的异常性疼痛。此外,PSPA-1在手术后第7天以1至100 pg /小鼠的剂量依赖性方式缓解了L5脊神经横断所产生的神经性疼痛。相反,它不影响热或机械伤害感受或炎症性疼痛。 PSPA-1通过NADPH-心肌黄递酶组织化学评估降低了神经性疼痛小鼠脊髓神经元型一氧化氮合酶活性的增加,并阻断了N-甲基-d-天冬氨酸诱导的异常性疼痛。这些结果表明,PSPA-1可能代表一类新的抗痛觉过敏药,可通过阻断谷氨酸一氧化氮途径来治疗神经性疼痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号